Cargando…

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Detalles Bibliográficos
Autores principales:	Saleh, Mansoor N., Patel, Manish R., Bauer, Todd M., Goel, Sanjay, Falchook, Gerald S., Shapiro, Geoffrey I., Chung, Ki Y., Infante, Jeffrey R., Conry, Robert M., Rabinowits, Guilherme, Hong, David S., Wang, Judy S., Steidl, Ulrich, Walensky, Loren D., Naik, Gurudatta, Guerlavais, Vincent, Vukovic, Vojislav, Annis, D. Allen, Aivado, Manuel, Meric-Bernstam, Funda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Corrections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361214/ https://www.ncbi.nlm.nih.gov/pubmed/35045962 http://dx.doi.org/10.1158/1078-0432.CCR-21-4241

Ejemplares similares

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
por: Saleh, Mansoor N., et al.
Publicado: (2021)

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
por: Pairawan, Seyed, et al.
Publicado: (2021)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

MDM4 (MDMX) and its Transcript Variants
por: Mancini, F, et al.
Publicado: (2009)

Role of Mdm2 and Mdmx in DNA repair
por: Eischen, Christine M.
Publicado: (2017)

Regulation of p53: a collaboration between Mdm2 and MdmX
por: Pei, Dongsheng, et al.
Publicado: (2012)

Controlling the Mdm2-Mdmx-p53 Circuit
por: Waning, David L., et al.
Publicado: (2010)

Length matters: C-terminal tails regulate Mdm2–MdmX complexes
por: Poyurovsky, Masha V.
Publicado: (2012)

Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
por: Ilic, Viktoria K., et al.
Publicado: (2022)

Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells
por: Egorova, Olga, et al.
Publicado: (2020)

Mdmx promotes genomic instability independent of p53 and Mdm2
por: Carrillo, Alexia M., et al.
Publicado: (2014)

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
por: Kon, Ning, et al.
Publicado: (2018)

Mouse modelling of the MDM2/MDMX−p53 signalling axis
por: Tackmann, Nicole R., et al.
Publicado: (2017)

The MDM2/MDMX/p53 axis in the adaptive stress response
por: Wang, Bing, et al.
Publicado: (2020)

The roles and regulation of MDM2 and MDMX: it is not just about p53
por: Klein, Alyssa M., et al.
Publicado: (2021)

p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX
por: Levy, Robin, et al.
Publicado: (2019)

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells
por: Gao, Chong, et al.
Publicado: (2019)

The alternative translated MDMX(p60) isoform regulates MDM2 activity
por: Tournillon, Anne-Sophie, et al.
Publicado: (2015)

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis
por: Jiang, Liren, et al.
Publicado: (2020)

MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling
por: Venkatesh, Divya, et al.
Publicado: (2020)

A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein
por: Valianatos, Georgios, et al.
Publicado: (2017)

Predicted Functions of MdmX in Fine-Tuning the Response of p53 to DNA Damage
por: Kim, Sohyoung, et al.
Publicado: (2010)

Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB
por: Hernández-Monge, Jesús, et al.
Publicado: (2016)

Rigorous Computational and Experimental Investigations on MDM2/MDMX-Targeted Linear and Macrocyclic Peptides
por: Diller, David J., et al.
Publicado: (2019)

Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network
por: Daftuar, Lilyn, et al.
Publicado: (2013)

Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations
por: Yu, Qiong, et al.
Publicado: (2014)

Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells
por: Slabáková, Eva, et al.
Publicado: (2015)

Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression
por: Chen, Si, et al.
Publicado: (2022)

The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2)
por: Hauck, Paula M., et al.
Publicado: (2017)

Insight Into the Binding Mechanism of p53/pDIQ-MDMX/MDM2 With the Interaction Entropy Method
por: Li, Mengxin, et al.
Publicado: (2019)

Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis
por: Gao, Chong, et al.
Publicado: (2019)

Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors
por: Cheng, Xiyao, et al.
Publicado: (2022)

Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
por: Wu, W, et al.
Publicado: (2015)

Stress-Induced Alternative Splice Forms of MDM2 and MDMX Modulate the p53-Pathway in Distinct Ways
por: Jacob, Aishwarya G., et al.
Publicado: (2014)

Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry
por: Zhu, Yan, et al.
Publicado: (2013)

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cells
por: Chopra, Harman, et al.
Publicado: (2017)

New insight into the role of MDMX in MDM2-mediated p53 degradation and anti-cancer drug development
por: Yang, Jing, et al.
Publicado: (2021)

A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize
por: Kosztyu, Pavlína, et al.
Publicado: (2019)

Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer
por: Swetzig, Wendy M., et al.
Publicado: (2016)

Is MDMX the better target?
por: Kon, Ning, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qpu8oc7autdhgafn4iirbg7472